Why did Baxter's financial results fall in 2022-23?

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends.

Will Baxter's financial prospects improve in 2025?

With medical utilization rising and supply chain pressures easing, we suspect Baxter's financial prospects will improve, especially in 2025 and beyond, as Baxter renegotiates significant contracts with group purchasing organizations. BAX is trading at a 46% discount.

How much money will Baxter receive from Vantive?

Baxter expects to receive approximately $3.50 billion in cash with net after-tax proceeds currently estimated to be in the range of $3.15 to $3.25 billion, exceeding original expectations. The transaction is a vital step in Baxter's ongoing strategic transformation and will establish Vantive as a global leader in kidney care.